Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(25%)
Results Posted
50%(1 trials)
Terminated
2(25%)

Phase Distribution

Ph not_applicable
2
25%
Ph phase_2
2
25%
Ph phase_3
1
13%
Ph phase_1
1
13%
Ph phase_4
2
25%

Phase Distribution

1

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Terminated2
Recruiting2
Completed2
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 42 (25.0%)
N/A2 (25.0%)

Trials by Status

terminated225%
not_yet_recruiting113%
recruiting225%
unknown113%
completed225%

Recent Activity

2 active trials
Showing 5 of 8
not_yet_recruitingphase_2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

NCT07485010
recruitingphase_1

Precision Antibiotic Dosing for Appendectomy

NCT06860802
completedphase_3

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

NCT03269994
recruitingphase_2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

NCT04310930
terminatednot_applicable

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

NCT01820793
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT06860802Phase 1

Precision Antibiotic Dosing for Appendectomy

Recruiting
NCT03269994Phase 3

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Completed
NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting
NCT01820793Not Applicable

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Terminated
NCT02474706Phase 4

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Terminated
NCT02703857Phase 4

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

Completed
NCT02985086Not Applicable

Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8